
    
      The purpose of this study is to determine the effectiveness of ACH-0144471 in improving
      anemia, as measured by increased blood hemoglobin, when given with eculizumab (a drug
      commonly used for treatment of PNH) for 24 weeks in patients with PNH.
    
  